These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)]. Klose G MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005 [No Abstract] [Full Text] [Related]
34. [Hyperlipidemia: decreasing lipid values and effects of statins]. Mathes P Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762 [No Abstract] [Full Text] [Related]
35. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL; J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286 [TBL] [Abstract][Full Text] [Related]
36. The evolving role of statins in the management of atherosclerosis. Vaughan CJ; Gotto AM; Basson CT J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252 [TBL] [Abstract][Full Text] [Related]
37. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
38. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
39. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Ferrières J Am J Cardiovasc Drugs; 2009; 9(2):109-15. PubMed ID: 19331439 [TBL] [Abstract][Full Text] [Related]
40. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Stein EA Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]